Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine

Vishal Panchal, Olha Taraschenko, Isabelle M. Maisonneuve, Stanley D. Glick

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

18-Methoxyroconaridine (18-MC), a synthetic derivative of ibogaine, reduces morphine self-administration and alleviates several signs of acute opioid withdrawal in rats. Although there is already well documented evidence of the mechanism mediating 18-MC's action to reduce the rewarding effects of morphine, nothing is known about the mechanism responsible for 18-MC's attenuation of opioid withdrawal. In vitro studies have demonstrated that 18-MC is a potent antagonist of α3β4 nicotinic receptors (IC 50 = 0.75 μM), which are predominantly located in the medial habenula and interpeduncular nuclei. Previous work indicating that α3β4 nicotinic receptors mediate 18-MC's effects on drug self-administration prompted us to assess whether brain areas having high or moderate densities of α3β4 receptors might be involved in 18-MC's modulation of opioid withdrawal. To test this possibility, 18-MC was locally administered into the medial habenula, interpeduncular nucleus and locus coeruleus of morphine-dependent rats; this treatment was followed by naltrexone to precipitate a withdrawal syndrome. Pretreatment with various doses of 18-MC into the locus coeruleus significantly reduced wet-dog shakes, teeth chattering, burying and diarrhea, while pretreatment into the medial habenula attenuated teeth chattering, burying, and weight loss. Some doses of 18-MC administered into the interpeduncular nucleus significantly ameliorated rearing, teeth chattering, and burying, while other doses exacerbated diarrhea and teeth chattering. The present findings suggest that 18-MC may act in all three nuclei to suppress various signs of opioid withdrawal.

Original languageEnglish (US)
Pages (from-to)98-104
Number of pages7
JournalEuropean Journal of Pharmacology
Volume525
Issue number1-3
DOIs
StatePublished - Nov 21 2005

Fingerprint

Habenula
Morphine
Opioid Analgesics
Tooth
Self Administration
Locus Coeruleus
Nicotinic Receptors
Diarrhea
Ibogaine
Naltrexone
Weight Loss
Dogs
18-methoxycoronaridine
Brain
Pharmaceutical Preparations
Interpeduncular Nucleus
Therapeutics

Keywords

  • Interpeduncular nucleus
  • Locus coeruleus
  • Medial habenula
  • Morphine
  • Naltrexone
  • Physical dependence

ASJC Scopus subject areas

  • Pharmacology

Cite this

Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. / Panchal, Vishal; Taraschenko, Olha; Maisonneuve, Isabelle M.; Glick, Stanley D.

In: European Journal of Pharmacology, Vol. 525, No. 1-3, 21.11.2005, p. 98-104.

Research output: Contribution to journalArticle

Panchal, Vishal ; Taraschenko, Olha ; Maisonneuve, Isabelle M. ; Glick, Stanley D. / Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. In: European Journal of Pharmacology. 2005 ; Vol. 525, No. 1-3. pp. 98-104.
@article{26fb75f6108f40ecadb836496295a10d,
title = "Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine",
abstract = "18-Methoxyroconaridine (18-MC), a synthetic derivative of ibogaine, reduces morphine self-administration and alleviates several signs of acute opioid withdrawal in rats. Although there is already well documented evidence of the mechanism mediating 18-MC's action to reduce the rewarding effects of morphine, nothing is known about the mechanism responsible for 18-MC's attenuation of opioid withdrawal. In vitro studies have demonstrated that 18-MC is a potent antagonist of α3β4 nicotinic receptors (IC 50 = 0.75 μM), which are predominantly located in the medial habenula and interpeduncular nuclei. Previous work indicating that α3β4 nicotinic receptors mediate 18-MC's effects on drug self-administration prompted us to assess whether brain areas having high or moderate densities of α3β4 receptors might be involved in 18-MC's modulation of opioid withdrawal. To test this possibility, 18-MC was locally administered into the medial habenula, interpeduncular nucleus and locus coeruleus of morphine-dependent rats; this treatment was followed by naltrexone to precipitate a withdrawal syndrome. Pretreatment with various doses of 18-MC into the locus coeruleus significantly reduced wet-dog shakes, teeth chattering, burying and diarrhea, while pretreatment into the medial habenula attenuated teeth chattering, burying, and weight loss. Some doses of 18-MC administered into the interpeduncular nucleus significantly ameliorated rearing, teeth chattering, and burying, while other doses exacerbated diarrhea and teeth chattering. The present findings suggest that 18-MC may act in all three nuclei to suppress various signs of opioid withdrawal.",
keywords = "Interpeduncular nucleus, Locus coeruleus, Medial habenula, Morphine, Naltrexone, Physical dependence",
author = "Vishal Panchal and Olha Taraschenko and Maisonneuve, {Isabelle M.} and Glick, {Stanley D.}",
year = "2005",
month = "11",
day = "21",
doi = "10.1016/j.ejphar.2005.09.060",
language = "English (US)",
volume = "525",
pages = "98--104",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine

AU - Panchal, Vishal

AU - Taraschenko, Olha

AU - Maisonneuve, Isabelle M.

AU - Glick, Stanley D.

PY - 2005/11/21

Y1 - 2005/11/21

N2 - 18-Methoxyroconaridine (18-MC), a synthetic derivative of ibogaine, reduces morphine self-administration and alleviates several signs of acute opioid withdrawal in rats. Although there is already well documented evidence of the mechanism mediating 18-MC's action to reduce the rewarding effects of morphine, nothing is known about the mechanism responsible for 18-MC's attenuation of opioid withdrawal. In vitro studies have demonstrated that 18-MC is a potent antagonist of α3β4 nicotinic receptors (IC 50 = 0.75 μM), which are predominantly located in the medial habenula and interpeduncular nuclei. Previous work indicating that α3β4 nicotinic receptors mediate 18-MC's effects on drug self-administration prompted us to assess whether brain areas having high or moderate densities of α3β4 receptors might be involved in 18-MC's modulation of opioid withdrawal. To test this possibility, 18-MC was locally administered into the medial habenula, interpeduncular nucleus and locus coeruleus of morphine-dependent rats; this treatment was followed by naltrexone to precipitate a withdrawal syndrome. Pretreatment with various doses of 18-MC into the locus coeruleus significantly reduced wet-dog shakes, teeth chattering, burying and diarrhea, while pretreatment into the medial habenula attenuated teeth chattering, burying, and weight loss. Some doses of 18-MC administered into the interpeduncular nucleus significantly ameliorated rearing, teeth chattering, and burying, while other doses exacerbated diarrhea and teeth chattering. The present findings suggest that 18-MC may act in all three nuclei to suppress various signs of opioid withdrawal.

AB - 18-Methoxyroconaridine (18-MC), a synthetic derivative of ibogaine, reduces morphine self-administration and alleviates several signs of acute opioid withdrawal in rats. Although there is already well documented evidence of the mechanism mediating 18-MC's action to reduce the rewarding effects of morphine, nothing is known about the mechanism responsible for 18-MC's attenuation of opioid withdrawal. In vitro studies have demonstrated that 18-MC is a potent antagonist of α3β4 nicotinic receptors (IC 50 = 0.75 μM), which are predominantly located in the medial habenula and interpeduncular nuclei. Previous work indicating that α3β4 nicotinic receptors mediate 18-MC's effects on drug self-administration prompted us to assess whether brain areas having high or moderate densities of α3β4 receptors might be involved in 18-MC's modulation of opioid withdrawal. To test this possibility, 18-MC was locally administered into the medial habenula, interpeduncular nucleus and locus coeruleus of morphine-dependent rats; this treatment was followed by naltrexone to precipitate a withdrawal syndrome. Pretreatment with various doses of 18-MC into the locus coeruleus significantly reduced wet-dog shakes, teeth chattering, burying and diarrhea, while pretreatment into the medial habenula attenuated teeth chattering, burying, and weight loss. Some doses of 18-MC administered into the interpeduncular nucleus significantly ameliorated rearing, teeth chattering, and burying, while other doses exacerbated diarrhea and teeth chattering. The present findings suggest that 18-MC may act in all three nuclei to suppress various signs of opioid withdrawal.

KW - Interpeduncular nucleus

KW - Locus coeruleus

KW - Medial habenula

KW - Morphine

KW - Naltrexone

KW - Physical dependence

UR - http://www.scopus.com/inward/record.url?scp=28044434214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044434214&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2005.09.060

DO - 10.1016/j.ejphar.2005.09.060

M3 - Article

VL - 525

SP - 98

EP - 104

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -